登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Integrin alpha V beta 8 >IT8-H52W4

Human Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer Protein, His Tag&Tag Free

热销产品推荐:

ACROBiosystems提供针对多种生物标志物靶标的lHC抗体产品,具有:验证充分、质量可靠、灵活授权及免疫组化检测服务支持!

分子别名(Synonym)

Integrin alpha V beta 8,ITGAV&ITGB8

表达区间及表达系统(Source)

Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free (IT8-H52W4) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 992 (ITGAV) & Glu 43 - Arg 684 (ITGB8) (Accession # NP_002201.1 (ITGAV) & NP_002205.1 (ITGB8)).

Predicted N-terminus: Phe 31 (ITGAV) & Glu 43 (ITGB8)

Request for sequence

蛋白结构(Molecular Characterization)

Integrin alpha V beta 8 Structure

Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free, produced by co-expression of ITGAV and ITGB8, has a calculated MW of 112.9 kDa (ITGAV) and 76.5 kDa (ITGB8). Subunit ITGAV is fused with polyhistidine tag at the C-terminus and followed by a acidic tail and subunit ITGB8 contains no tag but a basic tail at the C-terminus. The non-reducing (NR) protein migrates as 130-150 kDa (ITGAV) and 80-90 kDa (ITGB8) respectively due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM NaCl, pH8.0 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Integrin alpha V beta 8 SDS-PAGE

Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Integrin alpha V beta 8 ELISA

Immobilized Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT8-H52W4) at 5 μg/mL (100 μL/well) can bind Biotinylated Human Latent TGF-Beta 1, His,Avitag (Cat. No. TG1-H82Qb) with a linear range of 1-31 ng/mL (QC tested).

Protocol

Integrin alpha V beta 8 ELISA

Immobilized Human Fibronectin at 10 μg/mL (100 μL/well) can bind Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT8-H52W4) with a linear range of 0.313-10 μg/mL (Routinely tested).

Protocol

Integrin alpha V beta 8 ELISA

Immobilized Human Vitronectin at 5 μg/mL (100 μL/well) can bind Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT8-H52W4) with a linear range of 0.313-10 μg/mL (Routinely tested).

Protocol

 

背景(Background)

Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Integrin alpha V beta 8靶点信息
英文全称:integrin alpha V/beta 8
中文全称:整合素α-v/β-8复合体
种类:
上市药物数量:0详情
临床药物数量:2详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定